This database contains 48 studies, archived under the term: "cerebrospinal fluid"
Click here to filter this large number of results.
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study
Liu, Yongzhe,
Pan, Ningling,
Ma, Yaqun,
Zhang, Shengshuo,
Guo, Wenzhi,
Li, Haihong,
Zhou, Jingli,
Liu, Gang,
Gao, Minglong
Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, Norman R.,
Szabo, Paul,
Adamiak, Basia,
Burgut, Tuna,
Monthe, Carmen,
Lent, Richard W.,
Younkin, Steven,
Younkin, Linda,
Schiff, Richard,
Weksler, Marc E.
Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]
Safety of lumbar puncture procedures in patients with Alzheimer’s disease
Changes in cerebrospinal fluid (CSF) biomarkers are representative of biochemical changes in the brain. Collection of CSF by lumbar puncture (LP) is essential for biomarker analysis, which is important for research in neurodegenerative disorders. However, LP for research purposes has been controversial due to a reported high incidence of severe LP headache when using standard […]
CSF biomarker profile and diagnostic value in vascular dementia
Paraskevas, G. P.,
Kapaki, E.,
Papageorgiou, S. G.,
Kalfakis, N.,
Andreadou, E.,
Zalonis, I.,
Vassilopoulos, D.
Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 […]
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg, Agneta,
Darreh-Shori, Taher,
Peskind, Elaine,
Soininen, Hilkka,
Mousavi, Malahat,
Eagle, Gina,
Lane, Roger
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]
Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study
Freund-Levi, Yvonne,
Hjorth, Erik,
Lindberg, Catharina,
Cederholm, Tommy,
Faxén-Irving, Gerd,
Vedin, Inger,
Palmblad, Jan,
Wahlund, Lars-Olof,
Schultzberg, Marianne,
Basun, Hans,
Eriksdotter-Jönhagen, Maria
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer’s disease (AD).; Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.; Methods: Thirty-five patients (70.3 +/- 8.2 years) […]
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Zerr, I.,
Kallenberg, K.,
Summers, D. M.,
Romero, C.,
Taratuto, A.,
Heinemann, U.,
Breithaupt, M.,
Varges, D.,
Meissner, B.,
Ladogana, A.,
Schuur, M.,
Haik, S.,
Collins, S. J.,
Jansen, G. H.,
Stokin, G. B.,
Pimentel, J.,
Hewer, E.,
Collie, D.,
Smith, P.,
Roberts, H.,
Brandel, J. P.,
van Duijn, C.,
Pocchiari, M.,
Begue, C.,
Cras, P.,
Will, R. G.,
Sanchez-Juan, P.
Several molecular subtypes of sporadic Creutzfeldt-Jakob disease have been identified and electroencephalogram and cerebrospinal fluid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype. In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. […]